FILING ANALYSIS · WEDNESDAY, NOVEMBER 4
Harmony Biosciences Holdings, Inc. HRMY — 8-K: Results of Operations and Financial Condition
neutral
Harmony Biosciences reported Q3 WAKIX net revenue of $269 million and reiterated full-year guidance of $1.0-1.04 billion, while also announcing strong data for its orexin agonist BP-205, but no significant surprises or quantified beats were disclosed beyond reiterating existing guidance.
The filing
8-K - Harmony Biosciences Holdings, Inc. (0001802665) (Filer)
How we read impact: we grade every directional call in the open. Impact labels are AI estimates — not investment advice. See the full disclaimer.
Get filings like this every market day
The US SEC filings, UK RNS, EU notices, and Polymarket odds that matter — scored by AI, in one email.
Subscribe free →